





        
As deﬁned by Thomson ISI’s Essential Science 
Indicators, ‘Hot Papers’ are articles published within 
the last two years receiving the largest number of 
citations over the most recent two-month period. For 
the period ending September 2008, 2 of the 7 papers 
published in Nano Letters that were deﬁned as Hot 
Papers were focused on gold: 
 
On the quenching of semiconductor quantum dot 
photoluminescence by proximal gold nanoparticles
Pons, T.; Medintz, I. L.; Sapsford, K. E.; Higashiya, S.; 
Grimes, A. F.; English, D. S.; Mattoussi, H.
Nano Lett.; (Letter); 2007; 7(10); 3157-3164. DOI: 
10.1021/nl071729+ 
 
Arrays of iso-oriented gold nanobelts 
Chen, Y.; Milenkovic, S.; Hassel, A. W.
Nano Lett.; (Letter); 2008; 8(2); 737-742. DOI: 10.1021/
nl0725852
Imidazolium 
salts for GNP 
production 
Scientists at the Institute of Bioengineering 
and Nanotechnology (IBN) have reported the 
first use of imidazolium salts (IMSs) to convert 
carbohydrates into versatile chemical compounds 
for biofuel production. In the first reported study 
of the redox properties of IMSs published in the 
Journal of the American Chemical Society IBN 
researchers successfully synthesized uniform 
gold nanoparticles within seconds at room 
temperature using IMSs. The ultrafine (1-2 nm) 
nanoparticles remained stable for up to 6 months 
at 4°C. Unlike conventional synthesis techniques 
using borane or borohydride reduction processes, 
IBN’s method does not require any strong 
reducing reagent yet is able to produce gold 
nanoparticles under very mild reaction condition 
with remarkable efficiency. IBN’s new synthesis 
protocol could easily be scaled up for industrial 
applications.
See L. Zhao, C. Zhang, L. Zhuo, Y. Zhang and  
J. Y. Ying, “Imidazolium Salts: A Mild Reducing 
and Antioxidative Reagent,” Journal of the 
American Chemical Society, 130 (2008)  
12586-12587.
Final issue
This is the ﬁnal publication of NanoTech Gold 
News. In order to improve the timeliness of the 
information we have included in this newsletter, 
we have taken the decision to move to a new 
online format, speciﬁcally a ‘blog’ called Gold 
Innovations.
Visit http://www.goldinnovationsblog.com  








Nanopartz have announced that a revolutionary new 
manufacturing method has been developed for their 
nanorod products.  
 This new proprietary method, removes the cytotoxic 
cetyl trimethylammonium bromide (CTAB) capping 
agent necessary for manufacturing, replacing it with 
polyethylene glycol (PEG). PEG has a low toxicity and is 
used in a variety of products. It is the basis of a number 
of laxatives and skin creams and many other well 
known products. The combination of the gold nanorods 
with PEG coatings, under the name Ntracker, has 
shown half-life circulation times of greater than  
17 hours in mice. 
 For a number of years researchers have known of 
the advantages offered by gold nanorods for in-vivo  
and in-vitro applications. Gold nanorods have 
unprecedented photothermal absorption 
characteristics, efﬁciently converting light to heat  
as well as being very good light scatterers. These  
two properties are necessary for successful in-vivo 
therapeutics, imaging, and diagnostics. 
 However, the limitation on commercialising gold 
nanorods for in-vivo and in-vitro applications has been 
toxicity. Nanopartz now claims to have solved this 
problem with the release of their Ntracker nanorods 
 Other potential applications of gold nanorods 
include their use to improve the efﬁciency of solar 
cells, for use in negative refractive index materials, 
as well as for optical polarizers for sunglasses.
See www.nanopartz.com for more details3 
Non-cytotoxic gold 
nanorods for in-vivo 
therapeutics and 
imaging 
Midatech Group Ltd, a world leader in the design, 
synthesis and manufacture of biocompatible 
nanoparticles has announced the formation of a  
Basel-based Swiss drug development subsidiary, 
PharMida AG. Formation of this subsidiary follows an 
investment by a group of Switzerland-based private 
investors into Midatech Ltd. The mandate of PharMida 
is to develop a strong portfolio of clinically validated 
gold nanoparticle-drug combinations 3 
Midatech forms 
PharMida for 
applying gold 
nanotechnology  
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